Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism

✍ Scribed by Aaron R. Folsom; Mary Cushman; Michael Y. Tsai; Susan R. Heckbert; Nena Aleksic

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 66 KB
• Volume: 71
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.10229

✦ Synopsis

Abstract

Case–control studies have indicated increased risk of venous thrombosis associated with the prothrombin gene G20210A polymorphism and with elevated plasma prothrombin levels. We sought to confirm these results in a prospective population‐based study of 21,690 persons. We measured G20210A and prothrombin antigen on pre‐event blood samples of 302 participants who developed venous thromboembolism (VTE) and 626 participants who remained free of VTE. Approximately 4.0% of cases and 2.4% of controls carried the G20210A polymorphism, but only one of 137 African Americans did. The odds ratio in whites was 1.87 (95% CI = 0.85, 4.11)—higher for those who reported a prior history of VTE (OR = 5.44) than those reporting no VTE history (OR = 1.41) and in those with idiopathic VTE (OR = 2.51) than those with secondary VTE (OR = 1.38). There was no association between venous thromboembolism and plasma prothrombin antigen level. We estimated that the G20210A polymorphism may account for approximately 2.5% of venous thromboembolism events in United States whites. Am. J. Hematol. 71:285–290, 2002. © 2002 Wiley‐Liss, Inc.